Navigation Links
Organovo Holdings, Inc. to Webcast, Live, at RetailInvestorConferences.com December 5th
Date:12/2/2013

expand the use of our 3D tissues
  • Appointed Continental Stock Transfer & Trust as our transfer agent and registrar
  • About Organovo Holdings, Inc.:
    Organovo (NYSE MKT: ONVO) designs and creates functional, three-dimensional human tissues for medical research and therapeutic applications. The Company is collaborating with pharmaceutical and academic partners to develop human biological disease models in three dimensions. These 3D human tissues have the potential to accelerate the drug discovery process, enabling treatments to be developed faster and at lower cost. In addition to numerous scientific publications, their technology has been featured in The Wall Street Journal, Time Magazine, The Economist, and numerous others. Organovo is changing the shape of medical research and practice. Learn more at www.organovo.com.

    Sign up for email updates and connect with us on Twitter (@Organovo).

    About RetailInvestorConferences.com:
    Since 2010, RetailInvestorConferences.com has been the only monthly virtual investor conference series that provides an interactive forum for presenting companies to meet directly with retail investors using a graphically-enhanced online platform.

    Designed to replicate the look and feel of location-based investor conferences, Retail Investor Conferences unites PR Newswire's leading-edge online conferencing and investor communications capabilities with BetterInvesting's extensive retail investor audience network.

    Safe Harbor Statement 
    Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein ar
    '/>"/>

    SOURCE Organovo Holdings, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3

    Related medicine technology :

    1. Organovo Provides Guidance on Upcoming Retail Investor Conference
    2. Organovo Cautions Investors in Regards to "Short and Distort" Articles
    3. Organovo Holdings, Inc. Closes $46.6 Million Public Offering of Common Stock and Exercise of Over-Allotment Option
    4. Organovo Holdings, Inc. Prices $40.5 Million Public Offering of Common Stock
    5. Organovo and Methuselah Foundation Announce Funding of Bioprinting Research at Research Institutions
    6. Organovo Reports Fiscal 2013 Financial Results
    7. Organovo Holdings, Inc. Announces Change of Fiscal Year
    8. Organovo Reports 2012 Financial Results
    9. Organovo Holdings, Inc. announces redemption of 2.9 million outstanding warrants
    10. Organovo and OHSU Knight Cancer Institute Announce Collaboration in Cancer Research
    11. Market Boosted by Strong Tech Earnings: Bank of America Corp., MAP Pharmaceuticals Inc., Swingplane Ventures Inc., World Moto, Inc., Organovo Holdings, Inc.
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... 15, 2014  Zafgen, Inc., a leading biopharmaceutical company ... obese patients, today announced initial results from its ... of methionine aminopeptidase 2 (MetAP2), in patients with ... obesity.  These results showed improvements in body weight, ...
    (Date:1/14/2014)... , Jan. 14, 2014 HeartWare International, Inc ... of less invasive, miniaturized circulatory support technologies that are ... that it expects revenues for the fourth quarter of ... 2013 revenues to approximately $208 million. "Our ...
    (Date:1/14/2014)... North America,s leading business partnering event ... 30 th edition of its annual conference at the ... 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ) ... specialty chemical companies will take part in the conference, which ...
    Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
    ... Global public relations leader Porter Novelli today announced that ... Prix Galien USA Awards, which recognize excellence in biopharmaceutical ... condition. Porter Novelli will be responsible for raising awareness ... of submissions. The Prix Galien is ...
    ...   - Jayex , ... the Trust to , Instantly Review ... , Delivery of High-Quality Patient,Centred Care ... technology specialist, http://www.jaxex.com today,announces that United Lincolnshire NHS Trust (ULHT) has,selected ...
    Cached Medicine Technology:Porter Novelli Named Agency of Record for Prix Galien USA Awards 2United Lincolnshire Hospitals NHS Trust Selects Jayex QI Interactive Patient Survey and Information Management Kiosk 2
    (Date:4/23/2014)... J. O,Shea, M.D., scientific director at the National Institute ... been named the 2014 recipient of the Ross Prize ... open-access journal Molecular Medicine . The award will ... Academy of Sciences in Manhattan, followed by scientific presentations ... part of the National Institutes of Health. , The ...
    (Date:4/23/2014)... The American Society for Radiation Oncology (ASTRO) has ... Radiation Therapy for Endometrial Cancer: An ASTRO Evidence-Based ... therapy in the treatment of endometrial cancer. The ... 2014 issue of Practical Radiation Oncology ... The full-length guideline is available as an open-access ...
    (Date:4/23/2014)... Ind. - Purdue University researchers have developed a way ... cell by using tiny gold particles with tails of ... of agricultural and biological engineering, used gold nanoparticles to ... as BRCA1 messenger RNA splice variants, which can indicate ... of these mRNA splice variants in a cell can ...
    (Date:4/23/2014)... compound that targets an important brain receptor has a ... including relapse behavior, a University at Buffalo animal study ... this may be a novel lead compound for treating ... UB research was published as an online preview article ... study, the compound, RO5263397, severely blunted a broad range ...
    (Date:4/23/2014)... 2014Men whose testosterone falls below normal levels are more ... and have heart disease and type 2 diabetes. A ... for further testing and possible treatment is described in ... a peer-reviewed publication from Mary Ann Liebert, Inc., publishers. ... of Men,s Health website at http://www.liebertpub.com/jmh . ...
    Breaking Medicine News(10 mins):Health News:NIH scientist to receive Ross Prize in Molecular Medicine 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 3Health News:Gold nanoparticles help target, quantify breast cancer segments in a living cell 2Health News:Novel compound halts cocaine addiction and relapse behaviors 2
    ... A leading authority on the aging, health and retirement of ... the ability of Americans to provide for the long term ... November 12, Dr. Dychtwald will address members of the news ... importance of long term care planning. This topic is ...
    ... , PHILADELPHIA, Oct. 28 Health Partners announced ... the state Children,s Health Insurance Program (CHIP). CHIP, brought ... already begun enrolling members in Philadelphia County and will ... , CHIP offers quality health insurance to all uninsured ...
    ... Oct. 28 Carefx Corporation , ... and safety of patient care, is listed among the " ... by IDC, a leading IT market research and advisory firm. ... Oct. 26, profiles companies "with the vision and technology to have ...
    ... a subsidiary of Eisai Inc., announced today that it ... Biotech Inc. for development and commercialization of an antibody ... tumors. , Under the terms of the ... for the development, manufacture and sale of the antibody. ...
    ... Health Foundation today announced that it has awarded The ... to create education and outreach programs that empower pharmacists, ... misuse in their communities. , According to the Ohio ... Ohio high school students have reported using a prescription ...
    ... LONDON, October 28 Even though no-one wants to ... to look good at the,ubiquitous Christmas Party then follow the realbuzz.com guide ... diet and healthy living go out,the window, so now,s the time to ... - we wouldn,t be realbuzz.com if we didn,t offer this piece of,advice ...
    Cached Medicine News:Health News:Dr. Ken Dychtwald to Discuss Looming 'Caregiver Crunch' and the Importance of Proactive Long Term Care Planning 2Health News:Health Partners to Offer Health Insurance Through the Children's Health Insurance Program 2Health News:Carefx Named an Innovative Information Access 'Company to Watch' By Leading Market Research Firm 2Health News:Carefx Named an Innovative Information Access 'Company to Watch' By Leading Market Research Firm 3Health News:Morphotek(R), Inc. Announces a Licensing Deal With Centocor Ortho Biotech Inc. for Exclusive Development and Commercialization Rights for a Therapeutic Monoclonal Antibody 2Health News:Cardinal Health Foundation, The Ohio State University College of Pharmacy Join Forces to Prevent Prescription Medication Abuse 2Health News:The Countdown to Christmas - The realbuzz.com Guide to a Healthier You! 2
    ... a vacuum tube for the collection, transport ... immunophenotyping by flow cytometry. The preservative contained ... the white blood cell cluster of differentiation ... Patient samples collected in Cyto-Chex BCT are ...
    Streck-ONYX-Pack is specially designed for use on Coulter® ONYX Series instruments. Each pack contains diluent and lysing agent. The shelf life is one year from date of manufacture....
    ... reagent manufactured for the simultaneous quantitative ... cells. Streck-Lysing Agent IIIC is for ... S Plus II, III, IV, V, ... JT Series. The shelf life is ...
    Streck-CD3500 Hemoglobin/Lyse is a lytic reagent for the quantitative determination of hemoglobin on the Abbott CELL-DYN® 3500 and 3700. The shelf life is two years from the date of manufacture....
    Medicine Products: